James L Riley

List of Publications by Citations

Source: https://exaly.com/author-pdf/2901491/james-l-riley-publications-by-citations.pdf
Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

128 papers	17,797 citations	64 h-index	130 g-index
130 ext. papers	20,098 ext. citations	12.8 avg, IF	6.35 L-index

#	Paper	IF	Citations
128	CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. *Molecular and Cellular Biology*, **2005**, 25, 9543-53	4.8	1273
127	The CD28 signaling pathway regulates glucose metabolism. *Immunity*, **2002**, 16, 769-77	32.3	970
126	Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. *Nature Biotechnology*, **2008**, 26, 808-16	44.5	812
125	SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. *Journal of Immunology*, **2004**, 173, 945-54	5.3	793
124	Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. *Molecular Therapy*, **2009**, 17, 1453-64	11.7	786
123	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. *Proceedings of the National Academy of Sciences of the United States of America*, **2009**, 106, 3360-5	11.5	637
122	Cutting edge: Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. *Journal of Immunology*, **2002**, 168, 4272-6	5.3	583
121	PD-1 signaling in primary T cells. *Immunological Reviews*, **2009**, 229, 114-25	11.3	504
120	Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. *Science Translational Medicine*, **2012**, 4, 132ra53	17.5	456
119	Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. *Science Translational Medicine*, **2013**, 5, 197ra103	17.5	441
118	Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. *Clinical Cancer Research*, **2011**, 17, 4719-30	12.9	363
117	Human T regulatory cell therapy: take a billion or so and call me in the morning. *Immunity*, **2009**, 30, 656-65	32.3	358
116	Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB. *Nature Biotechnology*, **2002**, 20, 143-8	44.5	339
115	FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 4571-6	11.5	325
114	DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells. *Virology*, **2003**, 305, 115-23	3.6	296
113	The PDL1-PD1 axis converts human TH1 cells into regulatory T cells. *Science Translational Medicine*, **2011**, 3, 111ra120	17.5	286
112	Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. *Immunity*, **2011**, 35, 400-12	32.3	275

111	Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. *Science Translational Medicine*, **2011**, 3, 83ra41	17.5	272
110	Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors. *Clinical Cancer Research*, **2014**, 20, 4262-73	12.9	256
109	Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect. *Blood*, **2016**, 127, 1044-51	2.2	251
108	The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation. *Blood*, **2005**, 105, 13-21	2.2	248
107	Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 11790-5	11.5	239
106	CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients. *Science Translational Medicine*, **2012**, 4, 134ra62	17.5	216
105	Engineering artificial antigen-presenting cells to express a diverse array of co-stimulatory molecules. *Molecular Therapy*, **2007**, 15, 981-8	11.7	206
104	Control of HIV-1 immune escape by CD8 T cells expressing enhanced T-cell receptor. *Nature Medicine*, **2008**, 14, 1390-5	50.5	204
103	Antiviral effect and ex vivo CD4+ T cell proliferation in HIV-positive patients as a result of CD28 costimulation. *Science*, **1996**, 272, 1939-43	33.3	199
102	Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. *American Journal of Transplantation*, **2013**, 13, 3010-20	8.7	192
101	Strength of PD-1 signaling differentially affects T-cell effector functions. *Proceedings of the National Academy of Sciences of the United States of America*, **2013**, 110, E2480-9	11.5	192
100	The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. *Science Translational Medicine*, **2010**, 2, 55ra78	17.5	185
99	Differential regulation of HIV-1 fusion cofactor expression by CD28 costimulation of CD4+ T cells. *Science*, **1997**, 276, 273-6	33.3	182
98	Role of PD-1 during effector CD8 T cell differentiation. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4749-4754	11.5	178
97	Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. *American Journal of Transplantation*, **2011**, 11, 1148-57	8.7	177
96	Activation of class II MHC genes requires both the X box region and the class II transactivator (CIITA). *Immunity*, **1995**, 2, 533-43	32.3	166
95	CD40 ligand (CD154) triggers a short-term CD4(+) T cell activation response that results in secretion of immunomodulatory cytokines and apoptosis. *Journal of Experimental Medicine*, **2000**, 191, 651-60	16.6	160
94	Engineering lymphocyte subsets: tools, trials and tribulations. *Nature Reviews Immunology*, **2009**, 9, 704-16	36.5	156

93	Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. *Journal of Immunology*, **2008**, 180, 5794-8	5.3	156
92	Constitutive cell surface association between CD4 and CCR5. *Proceedings of the National Academy of Sciences of the United States of America*, **1999**, 96, 7496-501	11.5	156
91	Repression of the genome organizer SATB1 in regulatory T cells is required for suppressive function and inhibition of effector differentiation. *Nature Immunology*, **2011**, 12, 898-907	19.1	145
90	Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand. *FASEB Journal*, **2004**, 18, 1303-5	0.9	144
89	CD28 costimulation is essential for human T regulatory expansion and function. *Journal of Immunology*, **2008**, 181, 2855-68	5.3	133
88	CD28 and inducible costimulatory protein Src homology 2 binding domains show distinct regulation of phosphatidylinositol 3-kinase, Bcl-xL, and IL-2 expression in primary human CD4 T lymphocytes. *Journal of Immunology*, **2003**, 171, 166-74	5.3	132
87	Molecular analysis of G1B and G3A IFN gamma mutants reveals that defects in CIITA or RFX result in defective class II MHC and Ii gene induction. *Immunity*, **1994**, 1, 687-97	32.3	129
86	Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. *Blood*, **2008**, 112, 2847-57	2.2	123
85	Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. *PLoS Pathogens*, **2011**, 7, e1002020	7.6	118
84	Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. *Blood*, **2014**, 123, 61-9	2.2	116
83	FOXP3 is a homo-oligomer and a component of a supramolecular regulatory complex disabled in the human XLAAD/IPEX autoimmune disease. *International Immunology*, **2007**, 19, 825-35	4.9	111
82	Retinoic acid and rapamycin differentially affect and synergistically promote the ex vivo expansion of natural human T regulatory cells. *PLoS ONE*, **2011**, 6, e15868	3.7	109
81	Steric shielding of surface epitopes and impaired immune recognition induced by the ebola virus glycoprotein. *PLoS Pathogens*, **2010**, 6, e1001098	7.6	104
80	ICOS costimulation requires IL-2 and can be prevented by CTLA-4 engagement. *Journal of Immunology*, **2001**, 166, 4943-8	5.3	104
79	Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. *Clinical Immunology*, **2010**, 136, 348-63	9	103
78	CAR T cells for infection, autoimmunity and allotransplantation. *Nature Reviews Immunology*, **2018**, 18, 605-616	36.5	101
77	Efficient clinical scale gene modification via zinc finger nuclease-targeted disruption of the HIV co-receptor CCR5. *Human Gene Therapy*, **2013**, 24, 245-58	4.8	99
76	Large-scale production of CD4+ T cells from HIV-1-infected donors after CD3/CD28 costimulation. *Stem Cells and Development*, **1998**, 7, 437-48		99

75	Folate receptor alpha and caveolae are not required for Ebola virus glycoprotein-mediated viral infection. *Journal of Virology*, **2003**, 77, 13433-8	6.6	95
74	Clinical perspectives for regulatory T cells in transplantation tolerance. *Seminars in Immunology*, **2011**, 23, 462-8	10.7	87
73	cIAP2 is a ubiquitin protein ligase for BCL10 and is dysregulated in mucosa-associated lymphoid tissue lymphomas. *Journal of Clinical Investigation*, **2006**, 116, 174-81	15.9	84
72	Prostaglandin E2 impairs CD4+ T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. *Cancer Research*, **2006**, 66, 1114-22	10.1	82
71	Productive infection of neonatal CD8+ T lymphocytes by HIV-1. *Journal of Experimental Medicine*, **1998**, 187, 1139-44	16.6	72
70	Regulatory T cells and human myeloid dendritic cells promote tolerance via programmed death ligand-1. *PLoS Biology*, **2010**, 8, e1000302	9.7	70
69	A cell-based artificial antigen-presenting cell coated with anti-CD3 and CD28 antibodies enables rapid expansion and long-term growth of CD4 T lymphocytes. *Clinical Immunology*, **2002**, 105, 259-72	9	70
68	RNA fingerprints provide direct evidence for the inhibitory role of TGFbeta and PD-1 on CD4+ T cells in Hodgkin lymphoma. *Blood*, **2007**, 110, 3226-33	2.2	69
67	B and T lymphocyte attenuator-mediated signal transduction provides a potent inhibitory signal to primary human CD4 T cells that can be initiated by multiple phosphotyrosine motifs. *Journal of Immunology*, **2006**, 176, 6603-14	5.3	68
66	Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. *PLoS Pathogens*, **2017**, 13, e1006613	7.6	68
65	Generation of human islet-specific regulatory T cells by TCR gene transfer. *Journal of Autoimmunity*, **2017**, 79, 63-73	15.5	67
64	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. *Journal of Clinical Investigation*, **2016**, 126, 2642-60	15.9	63
63	Naïve and memory CD4 T cells differ in their susceptibilities to human immunodeficiency virus type 1 infection following CD28 costimulation: implicatip6s for transmission and pathogenesis. *Journal of Virology*, **1998**, 72, 8273-80	6.6	61
62	Mode of transmission affects the sensitivity of human immunodeficiency virus type 1 to restriction by rhesus TRIM5alpha. *Journal of Virology*, **2008**, 82, 11117-28	6.6	59
61	HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells. *Clinical Immunology*, **2003**, 106, 16-22	9	57
60	The paracaspase MALT1 controls caspase-8 activation during lymphocyte proliferation. *Molecular Cell*, **2008**, 31, 415-21	17.6	53
59	Genetic engineering of T cells for adoptive immunotherapy. *Immunologic Research*, **2008**, 42, 166-81	4.3	53
58	Human CD8+ T cells do not require the polarization of lipid rafts for activation and proliferation. *Proceedings of the National Academy of Sciences of the United States of America*, **2002**, 99, 15006-11	11.5	52

57	Modulation of susceptibility to HIV-1 infection by the cytotoxic T lymphocyte antigen 4 costimulatory molecule. *Journal of Experimental Medicine*, **2000**, 191, 1987-97	16.6	48
56	Engineered artificial antigen presenting cells facilitate direct and efficient expansion of tumor infiltrating lymphocytes. *Journal of Translational Medicine*, **2011**, 9, 131	8.5	46
55	Addition of deoxynucleosides enhances human immunodeficiency virus type 1 integration and 2LTR formation in resting CD4+ T cells. *Journal of Virology*, **2007**, 81, 13938-42	6.6	46
54	miR-146b antagomir-treated human Tregs acquire increased GVHD inhibitory potency. *Blood*, **2016**, 128, 1424-35	2.2	46
53	Adoptive immunotherapy: good habits instilled at youth have long-term benefits. *Immunologic Research*, **2008**, 42, 182-96	4.3	43
52	Recommendations for measuring HIV reservoir size in cure-directed clinical trials. *Nature Medicine*, **2020**, 26, 1339-1350	50.5	43
51	Engineering T Cells to Functionally Cure HIV-1 Infection. *Molecular Therapy*, **2015**, 23, 1149-1159	11.7	40
50	Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells. *PLoS ONE*, **2008**, 3, e3289	3.7	40
49	Extensive replicative capacity of human central memory T cells. *Journal of Immunology*, **2004**, 172, 6675-83	5.5	40
48	TCR affinity and specificity requirements for human regulatory T-cell function. *Blood*, **2012**, 119, 3420-30	2.2	37
47	MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression. *American Journal of Reproductive Immunology*, **1998**, 40, 385-94	3.8	37
46	The battle over mTOR: an emerging theatre in host-pathogen immunity. *PLoS Pathogens*, **2012**, 8, e1002864	7.4	35
45	Optimization of cGMP purification and expansion of umbilical cord blood-derived T-regulatory cells in support of first-in-human clinical trials. *Cytotherapy*, **2017**, 19, 250-262	4.8	32
44	Signalling to suit function: tailoring phosphoinositide 3-kinase during T-cell activation. *Trends in Immunology*, **2007**, 28, 161-8	14.4	32
43	Stabilized human TRIM5protects human T cells from HIV-1 infection. *Molecular Therapy*, **2014**, 22, 1084-1095	11.7	30
42	Ligation of CD28 by its natural ligand CD86 in the absence of TCR stimulation induces lipid raft polarization in human CD4 T cells. *Journal of Immunology*, **2005**, 175, 7848-54	5.3	30
41	Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments. *Cell Reports*, **2018**, 23, 741-755	10.6	28
40	The road to recovery: translating PD-1 biology into clinical benefit. *Trends in Immunology*, **2007**, 28, 48-50	14.4	28

39	Suppression of HIV-1 infection in primary CD4 T cells transduced with a self-inactivating lentiviral vector encoding a membrane expressed gp41-derived fusion inhibitor. *Clinical Immunology*, **2005**, 115, 26-32	9	28
38	Umbilical cord blood xenografts in immunodeficient mice reveal that T cells enhance hematopoietic engraftment beyond overcoming immune barriers by stimulating stem cell differentiation. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 1135-44	4.7	27
37	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus. *PLoS Pathogens*, **2016**, 12, e1005983	7.6	26
36	Improved Expansion and Function of Patient T Cells by a Serum-free Medium. *Molecular Therapy - Methods and Clinical Development*, **2018**, 8, 65-74	6.4	25
35	Cutting Edge: a novel, human-specific interacting protein couples FOXP3 to a chromatin-remodeling complex that contains KAP1/TRIM28. *Journal of Immunology*, **2013**, 190, 4470-3	5.3	24
34	The potent oncogene NPM-ALK mediates malignant transformation of normal human CD4(+) T lymphocytes. *American Journal of Pathology*, **2013**, 183, 1971-80	5.8	23
33	Dual CD4-based CAR T cells with distinct costimulatory domains mitigate HIV pathogenesis in vivo. *Nature Medicine*, **2020**, 26, 1776-1787	50.5	22
32	Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells. *Cancer Immunology, Immunotherapy*, **2011**, 60, 133-44	7.4	21
31	The role of co-stimulation in regulation of chemokine receptor expression and HIV-1 infection in primary T lymphocytes. *Seminars in Immunology*, **1998**, 10, 195-202	10.7	21
30	In Vitro Induction of Human Regulatory T Cells Using Conditions of Low Tryptophan Plus Kynurenines. *American Journal of Transplantation*, **2017**, 17, 3098-3113	8.7	20
29	Cutaneous T cell lymphoma expresses immunosuppressive CD80 (B7-1) cell surface protein in a STAT5-dependent manner. *Journal of Immunology*, **2014**, 192, 2913-9	5.3	19
28	HIV sequence variation associated with env antisense adoptive T-cell therapy in the hNSG mouse model. *Molecular Therapy*, **2010**, 18, 803-11	11.7	18
27	Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir. *Journal of Infectious Diseases*, **2017**, 215, S160-S171	7	17
26	Genetic engineering of T cells for immunotherapy. *Nature Reviews Genetics*, **2021**, 22, 427-447	30.1	17
25	Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection. *Journal of Immunology*, **2012**, 189, 3815-21	5.3	16
24	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV. *Frontiers in Immunology*, **2019**, 10, 2310	8.4	15
23	Selective reactivation of STING signaling to target Merkel cell carcinoma. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 13730-13739	11.5	15
22	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. *Blood*, **2020**, 136, 1722-1734	2.2	15

21	Translating In Vitro T Cell Metabolic Findings to In Vivo Tumor Models of Nutrient Competition. *Cell Metabolism*, **2018**, 28, 190-195	24.6	15
20	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. *Journal of Clinical Investigation*, **2021**, 131,	15.9	15
19	HIV-Resistant and HIV-Specific CAR-Modified CD4 T Cells Mitigate HIV Disease Progression and Confer CD4 T Cell Help In Vivo. *Molecular Therapy*, **2020**, 28, 1585-1599	11.7	12
18	Challenges and Opportunities of Using Adoptive T-Cell Therapy as Part of an HIV Cure Strategy. *Journal of Infectious Diseases*, **2021**, 223, 38-45	7	8
17	Influenza virus upregulates CXCR4 expression in CD4+ cells. *AIDS Research and Human Retroviruses*, **2000**, 16, 19-25	1.6	7
16	Low-density PD-1 expression on resting human natural killer cells is functional and upregulated after transplantation. *Blood Advances*, **2021**, 5, 1069-1080	7.8	7
15	Modulation of Hepatitis C Virus-Specific CD8 Effector T-Cell Function with Antiviral Effect in Infectious Hepatitis C Virus Coculture Model. *Journal of Virology*, **2017**, 91,	6.6	4
14	CTLA-4 and PD-1 Receptors Inhibit T-Cell Activation by Distinct Mechanisms.. *Blood*, **2004**, 104, 2657-2657	7.2	4
13	The human CD8 M-4 isoform dominant in effector memory T cells has distinct cytoplasmic motifs that confer unique properties. *PLoS ONE*, **2013**, 8, e59374	3.7	3
12	Response from Carroll et al.. *Trends in Microbiology*, **1997**, 5, 302-303	12.4	3
11	How to kill T cells for immunotherapy.. *Nature Cancer*, **2020**, 1, 1134-1135	15.4	2
10	NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation. *Cancer Research*, **2021**, 81, 3241-3254	10.1	2
9	Are affinity-enhanced T cells the future of HIV therapy?. *HIV Therapy*, **2009**, 3, 105-108		1
8	Engineering T Cells to Survive and Thrive in the Hostile Tumor Microenvironment. *Current Opinion in Biomedical Engineering*, **2021**, 100360	4.4	1
7	Discovery and Engineering of a Therapeutic Interfering Particle (TIP): a combination self-renewing antiviral		1
6	Characterization of CAR T cell expansion and cytotoxic potential during Ex Vivo manufacturing using image-based cytometry. *Journal of Immunological Methods*, **2020**, 484-485, 112830	2.5	1
5	Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory T cells in Cynomolgus macaque.. *Cell Reports Medicine*, **2022**, 3, 100614	18	0
4	Genetically Modified T Cells for Human Gene Therapy193-205		

3	Quantitation of HIV-1 Entry Cofactor Expression. *Methods in Molecular Medicine*, **1999**, 17, 219-26	
2	Engineered ovarian cancer artificial antigen presenting cells (aAPCs) support CD8+T cells growth and function. *FASEB Journal*, **2008**, 22, 519-519	0.9
1	Ultrasensitive antigen density discrimination by synNotch. *Cell Research*, **2021**, 31, 725-726	24.7